VIRUSCAN implementation has allowed to develop all the needed technological advancements to gather current knowledge in optomechanics, NEMs, native mass spectrometry and biophysics to current VIRUSCAN prototype, which still needs some adjustments for being installed in the clinical settings. Nevertheless, the stage of development achieved has allowed to deeply advance in the knowledge of the biophysical properties of the viruses. As result, an extensive database of biophysical properties of virus like particles that will allow clinicians a rapid diagnosis of a large number of viruses has been openly set. The goal of VIRUSCAN beyond this five years and a half it would be achieve the final integration of the whole technology, allowing to detect and identify virions in human samples from their mass and stiffness and asses its infectiveness.
Definitely, VIRUSCAN has led to initiate a radically new line of research and technology development whose transformational impact will not be limited to viral infections but it could also be extended later to other areas such as: nanoparticle/container based drug delivery; study of physical properties of a broad range of naturally occurring and synthetic nanoparticles relevant for materials science, energy and environment research; for food, pharma and agro applications (monitoring medium-large molecules, e.g. enzymes, proteins, etc). Advancements in the mass and stiffness spectrometry approach will nurture those areas in the future, thanks to the breakthrough and pioneering advancements made in VIRUSCAN, that could be crucial in a possible future bacterian pandemic due the current problem with the antibiotic resistance, one of the biggest threats to global health, food security, and development today.